share_log

Clover Biopharmaceuticals' COVID-19 Booster Candidate Neutralizes Omicron Subvariant During Trial

Clover Biopharmaceuticals' COVID-19 Booster Candidate Neutralizes Omicron Subvariant During Trial

三叶草生物制药公司的新冠肺炎助推剂候选药物在试验期间中和奥密克戎亚型
MT Newswires ·  2022/08/29 22:56

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发